To include your compound in the COVID-19 Resource Center, submit it here.

Analyst picks & changes

Alpha-Beta Technology Inc.

UBS Securities analyst Marc Ostro said that changes in the Phase III protocol of Alpha-Beta Technology Inc.'s Betafectin anti-infective in high-risk abdominal surgery patients, as a result of the FDA's review, will change the

Read the full 367 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers